Memo Therapeutics AG Starts U.S. Pivotal Phase II/III Clinical Trial with AntiBKV for Treatment of BKV Infection in Renal Transplant Patients
AntiBKV has potential to be first- and best-in-class treatment representing the sole option for large and growing number of patients. Interim data expected by the end of 2023; on track to reach patients in 2025.